Quantitative analysis for Lixte Biotechnology Holdings, Inc. (LIXT) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (61.0) (grade B). 23 signals analyzed (19 differentiated alt-data).
LIXT stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-24 | $4.05 | $3.64 | $3.71 |
| 2026-05-06 | $4.55 | $3.96 | $4.40 |
| 2026-05-18 | $5.27 | $4.65 | $4.70 |
| 2026-05-29 | $6.34 | $5.91 | $6.25 |
| 2026-06-10 | $7.16 | $6.80 | $6.89 |
| 2026-06-23 | $7.45 | $6.88 | $7.30 |
| 2026-07-06 | $7.70 | $6.54 | $7.34 |
| 2026-07-17 | $5.97 | $5.21 | $5.79 |
| 2026-07-30 | $4.26 | $4.03 | $4.17 |
| 2026-08-11 | $4.16 | $3.48 | $3.56 |
| 2026-08-21 | $4.44 | $4.24 | $4.30 |
| 2026-09-02 | $4.19 | $3.67 | $3.71 |
How Lixte Biotechnology Holdings, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IMMP | Immutep Limited | $69M | — |
| VANI | Vivani Medical, Inc. | $70M | — |
| GANX | Gain Therapeutics, Inc. | $70M | — |
| KPTI | Karyopharm Therapeutics Inc. | $68M | — |
View all Health Care stocks by valuation and signals →
LIXT scores Buy (61.0), resting on a single measured dimension: technicals at 73 out of 100. The remaining dimensions are unmeasured for this ticker rather than weak. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 73 |
StoQuant analyzes 23 signals (19 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Lixte Biotechnology Holdings, Inc. (LIXT): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/LIXT"><img src="https://stoquant.com/badge/LIXT.svg" alt="Lixte Biotechnology Holdings, Inc. (LIXT) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.